glp-1 receptor agonist medication Is Safe for Weight Loss? Peptides, Benefits & Risks Research shows GLP-1 receptor agonist

Description

South Korea and Australia approved local or imported GLP-1s but apply stringent BMI thresholds for publicly funded access, tempering early uptake

( Epub 2022/03/10 )

What is already known on this topic Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors reduce the risk of cardiovascular and renal events in patients with type 2 diabetes These drug classes are increasingly used in combination when previous therapy with other antihyperglycaemic drugs fails Whether the combined use of these drug classes results in improved cardiovascular and renal outcomes in the real world setting, compared with the use of either drug class alone, remains unclear What this study adds This population based cohort study aimed at emulating a randomised controlled trial The combined use of a GLP-1 receptor agonist and an SGLT-2 inhibitor was associated with a lower risk of cardiovascular and serious renal events, compared with either drug class alone These findings highlight the potential benefit of combining these two effective drug classes in preventing cardiovascular and renal events in the treatment of type 2 diabetes Data availability statement This study is based on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency

Semaglutide is one of the most extensively characterized incretin-based research peptides, with published preclinical and clinical research investigating its effects on glycemic endpoints, body composition, gastric emptying, appetite regulation, and cardiometabolic markers across obesity and metabolic disease models